Cargando…
Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells
CD14(+) dermal DCs (CD14(+) DDCs) have a natural capacity to activate naïve B-cells. Targeting CD14(+) DDCs is therefore a rational approach for vaccination strategies aimed at improving humoral responses towards poorly immunogenic antigens, for example, HIV-1 envelope glycoproteins (Env). Here, we...
Autores principales: | Matthews, Katie, Chung, Nancy P. Y., Klasse, Per Johan, Moutaftsi, Magda, Carter, Darrick, Salazar, André M., Reed, Steven G., Sanders, Rogier W., Moore, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659025/ https://www.ncbi.nlm.nih.gov/pubmed/23700434 http://dx.doi.org/10.1371/journal.pone.0063785 |
Ejemplares similares
-
Potent induction of antibody-secreting B-cells by human dermal-derived CD14+ dendritic cells triggered by dual toll-like receptor ligation
por: Matthews, K, et al.
Publicado: (2012) -
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012) -
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011) -
HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells
por: Shan, Meimei, et al.
Publicado: (2007) -
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21
por: Nam, Hyo Jung, et al.
Publicado: (2022)